Cancer cells are known to have a distinct metabolic profile and to exhibit significant changes in a variety of metabolic mechanisms compared to normal cells, particularly glycolysis and glutaminolysis, in order to cover their increased energy requirements. There is mounting evidence that there is a link between glutamine metabolism and the proliferation of cancer cells, demonstrating that glutamine metabolism is a vital mechanism for all cellular processes, including the development of cancer. Detailed knowledge regarding its degree of engagement in numerous biological processes across distinct cancer types is still lacking, despite the fact that such knowledge is necessary for comprehending the differentiating characteristics of many forms of cancer. This review aims to examine data on glutamine metabolism and ovarian cancer and identify possible therapeutic targets for ovarian cancer treatment.

Human papillomavirus (HPV) is a virtually necessary cause of cervical cancer, and HPV genotypes are categorized either as high-risk or low-risk based on their potential to cause malignancy of the cervix. HPV-DNA detection is used widely for screening women at risk. However, its clinical significance is not proven sufficiently in pregnancy. The aim of this review was to summarize published data referring to the integration of the HPV-DNA test in cervical cancer screening during pregnancy. PubMed and Scopus were searched for articles investigating the HPV-DNA test during pregnancy as a primary association; greater interest was placed on studies published after 2000. Retrieved articles reported similarities or discrepancies in the HPV-DNA test in pregnant women compared to those who are not pregnant, its accuracy, and its integration in cervical cancer screening. The HPV-DNA test may constitute a helpful tool utilized for monitoring, risk stratification, and triage of cases that require colposcopy. If combined with the HPV-mRNA test, this might improve its specificity. However, when compared to HPV-DNA detection rates in non-pregnant women, the results were ambiguous, without giving the opportunity to draw safe conclusions. Both those findings and the high cost hold it back from wide use. Hence, the Papanicolaou smear (Pap smear) is still the first-line diagnostic tool and colposcopy-guided cervical biopsy is the “gold standard” method for the management of cervical intraepithelial neoplasia (CIN) treatment during pregnancy.

A 19-year-old pregnant patient was diagnosed with primary toxoplasmosis infection. The patient was successfully treated with spiramycin and finally delivered normally a healthy boy. Serological tests for detection of anti-toxoplasma antibodies along with ultrasonography findings are the gold standard for the diagnosis. Spiramycin was used for embryo protection.

Polycythemia vera (PV) is one of the three main classic disorders of Philadelphia-negative myeloproliferative neoplasms (MPNs), with the other two being essential thrombocythemia (ET) and primary myelofibrosis (PMF). PV may develop (15%) in women of childbearing age (15–45 years), with an anticipated rate of roughly 0.3 per 100,000 people, although maintaining a male to female ratio predominance of about 2:1 and a peak prevalence in the sixth and seventh decades of life. Without always being presented with its actual clinical manifestations due to pregnancy itself, and most commonly due to iron deficiency, PV can be frequently missed and therefore belatedly diagnosed. We describe the case of a primipara woman in her 40s, without risk factors for thrombosis, who developed a portal vein occlusion 1.5 month postpartum after C-section and who had a delayed diagnosis of PV.

e117Pelvic floor disorders and urinary incontinence Poster Presentation Studying the newer TVT-O Abbrevo tape in comparison with the standard TVT-O tape for management of stress urinary incontinenceObjective: To study the newer TVT-O Abbrevo tape for management of SUI in terms of its complications and outcome compared to standard tape.Methods: All the patient who underwent TVT-O abbrevo for Stress Urinary Incontinence in the calendar year 2014 and were followed in the out patient clinic. They were studied for overall success, suboptimal outcome, complete cure and complications. The comparison was made with an Audit done in 2013 for with the standard TVT-O tape with equal number of patient.Place: Midlands Regional Hospital Mullingar Ireland Findings: We found the overall success rate of over 94% with the newer tape with fewer complications, though compared with our own previous audit with the standard tape the success rate was lower but it was not significant. The complete cure rate was as high as 89%. Both these rates were higher than the rates quoted by the tape manufacturing company (Ethicon) in their lone study mentioned on the website.Inference: The newer tape was introduced by Ethicon to reduce post operative complications by decreasing the overall length of the mesh by 38% and rightly so we saw no cases of mesh related complications with comparable outcome with the standard tape. Though the study has its limitations and it was not a controlled trial further studies can be under taken and help us care better for patients by decreasing mesh related complications and its immense implications on the medico-legal costs. http://dx.